Literature DB >> 3106808

Uniform detection of immunoglobulin-gene rearrangement in benign lymphoepithelial lesions.

A Fishleder, R Tubbs, B Hesse, H Levine.   

Abstract

The term "benign lymphoepithelial lesion" is used to describe the salivary-gland lymphocytic infiltration and epithelial changes typically found in association with Sjögren's syndrome. We used Southern blot hybridization techniques to examine the immunoglobulin genes in salivary-gland tissue derived from eight patients with benign lymphoepithelial lesions. Three of these patients had intrasalivary non-Hodgkin's lymphoma complicating the lesions, whereas the lesions in the remaining five were all histologically benign. Ten samples from the eight patients all revealed rearrangement of both the heavy-chain and light-chain immunoglobulin genes. In one of the patients in whom non-Hodgkin's lymphoma involved both the salivary-gland lesion and an ipsilateral lymph node, the rearrangements of the heavy-chain and light-chain immunoglobulin genes detected at the two sites were identical. One other patient had two distinct benign lymphoepithelial lesions removed two years apart. The rearrangements of the heavy-chain as well as the kappa light-chain genes detected in these two lesions were entirely different. These data suggest that B-cell clonal expansion has an integral role in the pathophysiology of the benign lymphoepithelial lesion and may explain the increased incidence of lymphoma noted in association with this disorder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106808     DOI: 10.1056/NEJM198704303161803

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  31 in total

1.  Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection.

Authors:  F Fend; L Quintanilla-Martinez; S Kumar; M W Beaty; L Blum; L Sorbara; E S Jaffe; M Raffeld
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

3.  Gastric "pseudolymphoma" with restricted light chain expression in a patient with obscure gastrointestinal blood loss.

Authors:  H Schulman; J Sickel; M S Kleinman; J T Adams
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

4.  Comparison of in situ hybridisation and polymerase chain reaction in the diagnosis of B cell lymphoma.

Authors:  A M McNicol; M A Farquharson; F D Lee; A K Foulis
Journal:  J Clin Pathol       Date:  1998-03       Impact factor: 3.411

5.  Establishment of a novel B cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals.

Authors:  S Shiokawa; J Nishimura; K Ohshima; N Uike; K Yamamoto
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

6.  Immunophenotypic and genotypic characterization of diffuse mixed non-Hodgkin's lymphomas.

Authors:  W E Katzin; M D Linden; A J Fishleder; R R Tubbs
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

Review 7.  Reactivation of Epstein-Barr virus in Sjögren's syndrome.

Authors:  R I Fox; M Luppi; H I Kang; P Pisa
Journal:  Springer Semin Immunopathol       Date:  1991

8.  Use of idiotype markers for cellular detection of monoclonal rheumatoid factor.

Authors:  C G Winearls; J G Sissons
Journal:  Springer Semin Immunopathol       Date:  1988

9.  Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome.

Authors:  D I Stott; F Hiepe; M Hummel; G Steinhauser; C Berek
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  Lymphocytic mastopathy associated with infiltrating lobular breast carcinoma.

Authors:  R Chetty; A E Butler
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.